CLU hosts Center for Nonprofit Leadership
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Cybersecurity scares spawn legislation, new businesses
Businesses, government entities and consumers are increasingly aware of the threat of cyberattacks. High-profile security breaches like the ones experienced by health insurer Anthem Blue Cross, JPMorgan Chase and social network LinkedIn have thrust cybersecurity into the national spotlight. As statewide and federal laws come into play, protecting online networks has become one of the Read More →
FDA declines to approve Novartis biosimilar for Amgen’s Neulasta
The Food and Drug Administration has declined for now to approve a copycat version of Amgen’s blockbuster drug Neulasta. Reuters reported July 19 that the FDA sent a letter to Swiss pharmaceutical Novartis at the end of June saying it was declining to approve the drug for now. Neulasta, made by Thousand Oaks-based biotech giant Read More →
Ceres third-quarter revenue up, losses down
Thousand Oaks-based ag-biotech company Ceres Inc. released third quarter results in documents filed with the Securities and Exchange Commission July 15. Ceres said revenues increased from $1.1 million during the third quarter of 2015 to $1.4 million during the third quarter of 2016. Net losses decreased from $5.9 million, or 98 cents per share, last Read More →
Amgen wins one, loses one in biosimilar battle
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Thousand Oaks city manager’s firing won’t hinder economy
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen partnering with Japanese company to develop biosimilars
Thousand Oaks-based biotech giant Amgen said July 13 it will partner with a Japanese company to develop and commercialize biosimilars in Japan. Under the partnership, Amgen will develop and manufacture biosimilars while Daiichi Sankyo will obtain marketing approval, distribution and commercialization rights in Japan for the products. The deal also includes several late-stage development drugs. Read More →
